Miravo Healthcare Announces the Canadian Commercial Launch of NeoVisc + and NeoVisc ONE for the Treatment of Pain and Improvement of Joint Functionality of the Knee

Miravo Healthcare Announces the Canadian Commercial Launch of NeoVisc + and NeoVisc ONE for the Treatment of Pain and Improvement of Joint Functionality of the Knee

 

MISSISSAUGA, ON, Jan. 13, 2021 /PRNewswire/ – Nuvo Pharmaceuticals Inc. (TSX: MRV) (OTCQX: MRVFF) d/b/a Miravo Healthcare (Miravo or the Firm), a Canadian centered healthcare firm with world attain and a diversified portfolio of business merchandise, immediately introduced the industrial launch of  NeoVisc+ 2 mL and NeoVisc ONE four mL in Canada. Each NeoVisc+ and NeoVisc ONE acquired Well being Canada approval in September 2020 for the remedy of ache and enchancment of joint performance in sufferers affected by degenerative (age-related modifications) or mechanical arthropathy (associated to overuse) of the knee.


Miravo Healthcare (CNW Group/Nuvo Pharmaceuticals Inc.)


“We proceed to develop our Canadian enterprise with the industrial launch of the 2 new line extensions of NeoVisc,” mentioned Jesse Ledger, Miravo’s President & Chief Government Officer. “The launch of NeoVisc+ and NeoVisc ONE gives docs and sufferers with progressive choices for the remedy of knee ache.”


About NeoVisc


NeoVisc+ and NeoVisc ONE are hyaluronic acid (HA) viscosupplements injected by a licensed healthcare skilled into the knee joint. In depth knowledge in peer reviewed literature signifies that intra-articular administration of HA is able to restoring the viscoelastic properties of the synovial fluid, with alleviation of ache and enchancment of joint mobility. Viscosupplements are sometimes administered to sufferers affected by the consequences of osteoarthritis (OA).


NeoVisc is offered in pre-filled syringes containing both 30 mg/2 mL (NeoVisc+) administered at weekly intervals for three weeks or a low quantity single injection, 60 mg/four mL (NeoVisc ONE). Each displays of NeoVisc scale back ache signs and enhance knee joint performance for as much as 6 months.


OA is the commonest type of arthritis, affecting practically 5 million Canadians. These numbers are rising: an estimated one in six Canadians may have OA by 2035, with a brand new prognosis each 60 seconds. (Arthritis Society of Canada). Historic knowledge signifies roughly 29% of Canadians reported being identified with OA of the knee, with prevalence charges of 13.zero% in sufferers 20-49, 38.three% in sufferers aged 50-64, rising to 48.7% in these 65 years and older. (Statistics Canada).


About Miravo Healthcare


Miravo is a Canadian centered, healthcare firm with world attain and a diversified portfolio of business merchandise.  The Firm’s merchandise goal a number of therapeutic areas, together with ache, allergy, and dermatology.  The Firm’s technique is to in-license and purchase growth-oriented, complementary merchandise for Canadian and worldwide markets.  Miravo’s head workplace is positioned in Mississauga, Ontario, Canada, the worldwide operations are positioned in Dublin, Eire and the Firm’s manufacturing facility is positioned in Varennes, Québec, Canada.  The Varennes facility operates in a Good Manufacturing Practices (GMP) surroundings respecting the U.S, Canada and E.U. GMP rules and is usually inspected by Well being Canada and the U.S. Meals and Drug Administration.  For extra data, please go to www.miravohealthcare.com.


Ahead-Trying Statements
This press launch comprises “forward-looking data” as outlined underneath Canadian securities legal guidelines (collectively, “forward-looking statements”). The phrases “plans”, “expects”, “doesn’t count on”, “targets”, “search”, “technique”, “future”, “estimates”, “intends”, “anticipates”, “doesn’t anticipate”, “projected”, “believes” or variations of such phrases and phrases or statements to the impact that sure actions, occasions or outcomes “could”, “will”, “may”, “would”, “ought to”, “may”, “seemingly”, “happen”, “be achieved” or “proceed” and related expressions determine forward-looking statements. As well as, any statements that seek advice from expectations, intentions, projections or different characterizations of future occasions or circumstances include forward-looking statements. 


Ahead-looking statements should not historic information however as an alternative signify administration’s expectations, estimates and projections relating to future occasions or circumstances, together with the anticipated receipt of sure milestone and royalty funds, the anticipated launch of sure merchandise and the potential influence of COVID-19. Such forward-looking statements are certified of their entirety by the inherent dangers, uncertainties and modifications in circumstances surrounding future expectations that are tough to foretell and lots of of that are past the management of the Firm. Ahead-looking statements are essentially based mostly on numerous estimates and assumptions that, whereas thought-about affordable by administration of the Firm as of the date of this press launch, are inherently topic to vital enterprise, financial and aggressive uncertainties and contingencies and will show to be incorrect. Materials components and assumptions used to develop the forward-looking statements, and materials threat components that might trigger precise outcomes to vary materially from the forward-looking statements, embrace however should not restricted to, the validity of the ‘907 and ‘285 Patents claims, the result of ongoing patent litigation, the potential influence of COVID-19 on the Firm’s operations, enterprise and monetary outcomes and different components, lots of that are past the management of Miravo.  Further components that might trigger Miravo’s precise outcomes and monetary situation to vary materially from these indicated within the forward-looking statements embrace, amongst others, the chance components included in Miravo’s most up-to-date Annual Info Kind dated February 24, 2020 underneath the heading “Dangers Elements”, and as described every now and then within the studies and disclosure paperwork filed by Miravo with Canadian securities regulatory companies and commissions. These and different components needs to be thought-about rigorously and readers shouldn’t place undue reliance on Miravo’s forward-looking statements. Ahead-looking statements shouldn’t be learn as ensures of future efficiency or outcomes and won’t essentially be correct indications of whether or not or not the occasions at or by which such efficiency or outcomes will probably be achieved.


All forward-looking statements are based mostly solely on data at present obtainable to the Firm and are made as of the date of this press launch. Besides as expressly required by relevant Canadian securities regulation, the Firm assumes no obligation to publicly replace or revise any forward-looking assertion, whether or not because of new data, future occasions or in any other case. All forward-looking statements on this press launch are certified by these cautionary statements.


 


Cision View unique content material to obtain multimedia:http://www.prnewswire.com/news-releases/miravo-healthcare-announces-the-canadian-commercial-launch-of-neovisc-and-neovisc-one-for-the-treatment-of-pain-and-improvement-of-joint-functionality-of-the-knee-301207095.html


SOURCE Nuvo Prescribed drugs Inc.

 

Leave a Reply

Your email address will not be published. Required fields are marked *